Skip to main content

rp2

Generic: sturlimgene erparepvec·Code: RP2

rp2: developed by 1 company · 5 clinical trials tracked.

rp2 evidence translation

What we can confirm

What it means

Source-backed records connect rp2 to REPL; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could rp2 → REPL affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 0 study sponsors

Related indications

Hepatocellular Carcinoma; Gastric Adenocarcinoma; CancerBiliary Tract CancerCancerHepatocellular Carcinoma

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
Replimune Group, Inc. (REPL)
Hepatocellular Carcinoma; Gastric Adenocarcinoma; Cancer
Phase 1
Clinical Trials (5)

Phase II Study of Neoadjuvant RP2 in Combination With Preoperative Flot for Patients With Stage II or Higher, Non-metastatic Gastroesophageal Adenocarcinoma

NCT07059611·Phase 2·REPL
Not yet recruiting

Primary endpoint: Pathologic complete response

Interventionalopen34 targetStarted 2026-04Completion 2029-111 site · United StatesAbramson Cancer Center at Penn Medicine

A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab Versus Ipilimumab in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406·Phase 3·REPL
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen280 targetStarted 2024-12Completion 2031-1031 sites · United Kingdom, United StatesReplimune Inc.

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

NCT05733598·Phase 2·REPL
Recruiting

Primary endpoint: Overall Response Rate per modified RECIST 1.1

Interventionalopen60 targetStarted 2024-08Completion 2028-0711 sites · United StatesReplimune Inc.

A Phase 2 Clinical Trial Investigating Oncolytic Immunotherapy in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With Advanced Microsatellite Stable and Mismatch Repair Proficient Colorectal Carcinoma

NCT05733611·Phase 2·REPL
Terminated

Primary endpoint: Objective Response Rate (ORR)

Interventionalopen5 targetStarted 2023-06Completion 2025-082 sites · United StatesReplimune Inc.

An Open-Label, Multicenter, Phase 1 Study of RP2 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors

NCT04336241·Phase 1·REPL
Recruiting

Primary endpoint: Percentage of adverse events (AEs)

Interventionalopen36 targetStarted 2019-10Completion 2028-047 sites · Spain, United KingdomReplimune Inc.

Frequently asked questions

Who is developing rp2?

rp2 is being developed by Replimune Group, Inc..

How many clinical trials involve rp2?

BioSniper tracks 5 clinical trials involving rp2.